Evaluation of Fentanyl Exposure Effects on Butyrylcholinesterase Activity as a Tool for Future On-Site Detection Methods.

The prominence of fentanyl and fentanyl analogues or Fentanyl Related Substances (FRS) has driven a nationwide crisis of opioid overdoses, which significantly presents an issue for public health and safety. Originally developed for medical purposes, fentanyl and FRS have become critical contributors to opioid overdose deaths due to their distribution, availability, and potency. This study examined toxicodynamic properties between butyrylcholinesterase (BChE) and fentanyl analogues via Ellman's assay.

Who Shot the Bullet? Projectile Composition Characterization as an Evolutionary Method for Enhancement of Ballistics Evidence Analysis.

Toolmark and Firearm examiners' opinions have fallen under scrutiny as inadmissible ballistics evidence has led to the possibility of wrongful convictions and cold cases that could have been solved with the presence of a physical bullet, casing, and/or weapon at the crime scene. This research provides a solution for subjective-based conclusions and the absence of physical evidence altogether. Analysis of bullet material using Atomic Absorption Spectroscopy (AAS) has distinguished bullet composition between manufacturers from a surface scratch.

Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study).

Objective: Identify patient experience and preference towards thrombopoietin-receptor agonists (TPO-RAs) in treatment of immune thrombocytopenia (ITP) in the Netherlands.

Methods: The Thrombopoietin-Receptor Agonist Patient experience (TRAPeze) survey used a discrete choice experiment (DCE) to elicit patient preferences and a patient burden survey (PBS) to evaluate the clinical and social impact of ITP. TRAPeze collected responses from 6th October to 19th November 2021.

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.

Background: Primary immune thrombocytopenia is an autoimmune disorder mediated partly by platelet autoantibodies, resulting in thrombocytopenia, bleeding, and constitutional symptoms. Efgartigimod, a first-in-class novel human IgG1 Fc fragment, binds the neonatal Fc receptor with high affinity and thus reduces serum IgG concentrations, including autoantibodies. The objective of this study was to evaluate the efficacy and safety of efgartigimod in adults with persistent and chronic primary immune thrombocytopenia.